Daily Caller: Avastin-Lucentis battle comes down to patient choice
This opinion piece, from a website “The Daily Caller,” makes several good points about the danger of government overreach in healthcare. Its author, Sally Pipes, heads the Pacific Research Institute and has written extensively about Obamacare, including her latest book, The Pipes Plan: The Top Ten Ways to Dismantle and Replace Obamacare (Regnery 2012).
Click the headline to read the entire article; I’ve selected an excerpt, below:
This pointed conflict over patient safety provides an example of the danger that government regulation can bring to the quality of healthcare. Regardless of the drug, condition, or patient in question, individualized care is essential. The most effective medical system is one where patients and physicians have access to a wide array of treatments, and can make informed choices without fear of penalty.
As I have written in the past:
Ultimately, the choice of treatment should be left up to individual doctors and their patients. By restricting health coverage and limiting treatment options, government bureaucrats are intruding on the doctor-patient relationship and putting peoples’ health at risk.
An off-label drug may help one patient but not others. But overreaching regulators, with their one-size-fits-all ideology and focus on cost effectiveness rather than medical effectiveness, are a danger to every patient.